PHARMA TECH

Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Phio Pharmaceuticals Corp | October 26, 2020

Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Phio Pharmaceuticals Corp. a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020.

Spotlight

Pharmacokinetics describes how the body affects a specific xenobiotic/chemical after administration through the mechanisms of absorption and distribution, as well as the metabolic changes of the substance in the body (e.g. by metabolic enzymes such as cytochrome P450 or glucuronosyltransferase enzymes), and the effects and routes of excretion of the metabolites of the drug.[2] Pharmacokinetic properties of chemicals are affected by the route of administration and the dose of administered drug.

Related News

US and UK 'lead push against global patent pool for Covid-19 drugs'

The guardian | May 18, 2020

Ministers and officials from every nation will meet via video link on Monday for the annual world health assembly, which is expected to be dominated by efforts to stop rich countries monopolising drugs and future vaccines against Covid-19. As some countries buy up drugs thought to be useful against the coronavirus, causing global shortages, and the Trump administration does deals with vaccine companies to supply America first, there is dismay among public health experts and campaigners who believe it is vital to pull together to end the pandemic. While the US and China face off, the EU has taken the lead. The leaders of Italy, France, Germany and Norway, together with the European commission and council, called earlier this month for any innovative tools, therapeutics or vaccines to be shared equally and fairly.

Read More

PHARMA TECH

Tetrate-Named-2021-Cool-Vendor-in-Cloud-Computing-by-Gartner

Omnicell | November 11, 2021

Omnicell, Inc. a leading provider of medication management solutions and adherence tools for health systems and pharmacies, and Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition, are collaborating to provide U.S. hospitals and health systems with innovative new pharmacy technology designed to support safety and efficiency in dispensing of controlled substances in patient care areas. Managing controlled substances is a significant challenge for hospitals and clinics. According to a recent study, more than 148 million doses of medicine were lost in 2019, compromising both patient and workforce safety.1 Omnicell’s Controlled Substance Dispenser (CSD) is a leading high-volume, automated single dose dispensing solution designed to help pharmacies better manage controlled substances, reduce diversion, and save nursing time. By providing only one dose at a time, the CSD is designed to eliminate the need for countbacks and decrease the time required to resolve discrepancies to provide nurses more time for direct patient care and discourage diversion.2 Through its relationship with Fresenius Kabi, Omnicell has designed new cassettes for its CSD specifically for Fresenius Kabi Simplist® MicroVault® prefilled syringes that will provide customers more flexibility with their medication supply chain and enhanced controlled substance management initiatives. The new Fresenius Kabi cassettes for the Omnicell CSD are available now. Fresenius Kabi Simplist® MicroVault® prefilled syringes are used by hospitals in the United States in an effort to help reduce the amount of time nurses spend preparing doses and documenting waste. The error rate is four times lower using these prefilled syringes compared with traditional medication administration practices.3 The new cassettes for the Omnicell CSD will accommodate MicroVault® packaging for a variety of low-dose narcotic medications including morphine, hydromorphone, and fentanyl. The syringes are manufacturer-prepared in the United States, with a 24-month shelf life, and are single-unit doses, supporting best practices for medication administration. “Omnicell is committed to addressing the biggest challenges in pharmacy care delivery through technology Through innovative collaborations with healthcare leaders like Fresenius Kabi, we’re delivering the solutions designed to help our customers manage controlled substances, reduce diversion, optimize inventory, and enhance clinical workflows to support optimal care and patient safety.” Nish Parekh, Omnicell’s Vice President of Product Management for Point of Care Solutions “Fresenius Kabi is committed to medication safety and the responsible use of controlled substances,” said Angie Lindsey, Vice President of Marketing for Fresenius Kabi USA. “The combination of Omnicell’s Controlled Substance Dispenser automation workflow with Fresenius Kabi Simplist® MicroVault® prefilled syringes will offer healthcare providers advanced tools and technology to achieve these aims.” The Fresenius Kabi-Omnicell relationship and offering is an important step toward the vision of the Autonomous Pharmacy, a roadmap to develop a zero-error, fully automated medication management infrastructure. Through Omnicell’s industry leading medication management portfolio of hardware, software, and technology-enabled services delivered through the cloud, many health systems and retail pharmacies are realizing how connected technology and intelligence can help solve some of the most pressing challenges in medication management. About Fresenius Kabi Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help treat critical and chronic conditions. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi. About Omnicell Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 60,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. Forward-Looking Statements Certain statements contained in this press release relate to future plans and objectives regarding Omnicell’s products and services. These statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, those described in the Risk Factors section of Omnicell’s most recent annual report on Form 10-K and quarterly report on Form 10-Q and in the Company’s other filings with the U.S. Securities and Exchange Commission. Forward-looking statements should be considered in light of these risks and uncertainties. Investors are cautioned not to place undue reliance on forward-looking statements. All forward looking statements contained in this press release speak only as of the date of this press release. Omnicell undertakes no obligation to update such statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.

Read More

PHARMA TECH

Hologic Launches Panther Trax for High Volume Molecular Testing

Hologic | December 24, 2021

Hologicannounced that it has completed regulatory filings needed to make Panther Trax® available in a number of countries and regions. Launch of Panther Trax represents the latest addition to the Panther® Scalable Solutions portfolio of products, offering the ultimate in lab automation by physically linking multiple Panther instruments together into a single, powerful workcell that allows labs to increase testing volumes without increasing staff. Panther Trax is now listed as a Class I medical device with the United States Food and Drug Administration, CE-marked for diagnostic use in Europe, and will also be commercially available in Canada, Australia and New Zealand. “Clinical laboratories have performed heroically, meeting unprecedented demand for close to two years now due to the COVID-19 pandemic. It is the job of manufacturers like Hologic to continue to innovate and enable our lab partners to accomplish more with less, ensuring they manage their workloads while responding to further potential surges in COVID testing.” Kevin Thornal, president, Diagnostic Solutions Division at Hologic The Panther system, initially launched in Europe in 2010, offers random access and full automation for molecular testing. It provides a broad assay menu that includes tests for women’s health, sexually transmitted infections, respiratory health, viral load and COVID-19 testing, as well as Open Access™ functionality for laboratory developed tests. This broad menu enables labs to consolidate molecular testing onto a single platform. The Panther system serves as the foundation for optional add-ons including: Panther® Fusion, which launched in 2017 and provides additional IVD menu and the Open Access functionality to run LDTs; Panther® Plus, which gives labs greater flexibility, walk-away time and throughput; and Panther® Link, which virtually connects multiple instruments to share data and reagents while providing a centralized dashboard to monitor all instruments. These scalable solutions address the needs of today’s laboratories, allowing them to increase operational capacity and testing volumes at their own pace, while building on the flexibility, and streamlined user experience they require. With Panther Trax, labs can customize configuration to meet space constraints and minimize facility costs. Taken together, the suite of Panther Scalable Solutions offered by Hologic significantly expands upon the proven performance and reliability of the foundational Panther system. About the Panther System The Panther system for molecular diagnostics is a best-in-class fully automated, sample-to-result platform with adaptable workflow options and consolidated testing menu. The Panther Fusion system provides an expanded in-vitro diagnostics menu, as well as Open Access functionality to run LDTs. Hologic’s Panther and Panther Fusion systems now offer 19 FDA-cleared assays and up to 22 assays outside the U.S. depending on the region. This high-throughput molecular diagnostic platform combines comprehensive sexual health, cervical health, viral load, respiratory testing and open channel functionality on a fully automated system. About Hologic Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment.

Read More

Spotlight

Pharmacokinetics describes how the body affects a specific xenobiotic/chemical after administration through the mechanisms of absorption and distribution, as well as the metabolic changes of the substance in the body (e.g. by metabolic enzymes such as cytochrome P450 or glucuronosyltransferase enzymes), and the effects and routes of excretion of the metabolites of the drug.[2] Pharmacokinetic properties of chemicals are affected by the route of administration and the dose of administered drug.